Lupin’s US arm gets tentative nod from US FDA for Generic Avelox Tablets

06 Sep 2016 Evaluate

Pharma Major Lupin’s US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. has received tentative approval for its Moxifloxacin Hydrochloride Tablets, 400 mg from the United States Food and Drug Administration (US FDA) to market a generic version of Bayer Healthcare Pharmaceuticals Inc.'s Avelox Tablets, 400 mg (base).

Lupin’s Moxifloxacin Hydrochloride Tablets, 400 mg are the AB rated generic equivalent of Bayer Healthcare Pharmaceuticals Inc.'s Aveloxe Tablets, 400 mg (base). It is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria in certain conditions. 

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×